Eisbach Bio

🚨 2nd Recruitment call is now open! 🚨 ⚠️There are still 3 Doctoral Candidate positions available in NUCLEAR! If you're ready to dive into innovative research in metabolic regulation of genome, join our international program. 📩Apply now: nuclear-dn.eu/recruitment/

🚨 16 PhD positions open in early 2025! 🚀 Join NUCLEAR for cutting-edge research on nuclear metabolism, cell identity, and genome function. 🌍 Details on projects, eligibility & applications coming soon.Stay tuned! #PhDOpportunities#MarieCurieActions 👉nuclear-dn.eu

🌟 Eisbach Bio 🤝 Texas 🌟 We are proud to announce that Eisbach has received a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (@CPRITTexas) to support the clinical development of EIS-12656! Read more: #2a9e" target="_blank" rel="nofollow noopener">eisbach.bio/#2a9e

📢 Visit our press release published today to learn about the exciting NUCLEAR project, coordinated by @MarcusBuschbeck at the @CarrerasIJC . Discover more about training new experts in #metabolic regulation of #genome function! 🧬✨ Read more: carrerasresearch.org/en/news/the-jo…

🧬 Shaping the Future of #Biomedicine with the NUCLEAR project 🧬 Eisbach is set to train the next generation of scientists in the #metabolic regulation of genome function through the EU-funded research network NUCLEAR 🌍 Read the press release here: #2a9e" target="_blank" rel="nofollow noopener">eisbach.bio/#2a9e

The @US_FDA has granted Eisbach Bio IND approval for its drug candidate EIS-12656, 👏, the world's first small molecule ##therapy targeting the molecular machine ALC1, which is key #DNA damage and repair in several solid #tumor indications. Learn more: #2a9e" target="_blank" rel="nofollow noopener">eisbach.bio/#2a9e

Eisbach is excited to announce a $4.5 million investment from the Cancer Focus Fund to support its first-in-human Phase 1/2 #Trial of EIS-12656 for refractory advanced solid #tumors. Read the press release: #2a9e" target="_blank" rel="nofollow noopener">eisbach.bio/#2a9e

Eisbach is proud to announce the start of a Phase 1, first-in-human clinical trial for EIS-10700, a COVID-19 antiviral targeting the RNA helicase of SARS-CoV-2. Read the full press release here: #2a9e" target="_blank" rel="nofollow noopener">eisbach.bio/#2a9e #clinicaltrials #covid19 #drugdevelopment #TeamEisbach

A nucleic acid chemistry cluster to shape Germany’s R&D future – @eisbachbio member of the winning C-NATM cluster. The cluster has emerged as one of the winners in the Clusters4Future competition funded by BMBF. Read more about our collaboration: eisbach.bio/CNATM/

“In our collaboration with Eisbach, we are hoping to advance additional much-needed therapeutic options that can improve patients’ lives,” says our Dr. Philip Jones: fal.cn/3lqVM @eisbachbio #CancerMoonshot #EndCancer

We’re proud to collaborate with Eisbach to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution: fal.cn/3lpOX @eisbachbio #CancerMoonshot #EndCancer

@Eisbachbio is excited to announce a strategic research collaboration with The University of Texas @MDAndersonNews to jointly develop medicines targeting epigenetic machinery in oncology. Read the full press release here: eisbach.bio/press-release-… #oncology #research

@Eisbach is excited to announce a strategic research collaboration with The University of Texas @MDAndersonNews to jointly develop medicines targeting epigenetic machinery in oncology. Read the full press release here: eisbach.bio/press-release-… #oncology #research

Join our fight against cancer! To leverage our allosteric platform, we are growing our incredible team and are now recruiting (d/f/m) in Munich: - Full-time Principal Scientist and - Full-time Laboratory Head Let's treat cancer smarter. Together. eisbach.bio/career/

Eisbach Bio is thrilled to announce financial support of €6.7M from the Bavarian Government for the development of targeted SARS-CoV-2 antivirals. More details about the BayTherapie grant in our press release: eisbach.bio/press-release-… #BayTherapie2020 #COVID19 #TeamEisbach

🚀 Start-up - pandemic - success: How does that go together? Find out in the panel discussion: How to lift off during a pandemic - news from the frontline at our upcoming start-up event w/ @Tubulis_GmbH #ViGeneron @eisbachbio @deepchealth @HorstDomdey ▶️ lnkd.in/dRtkXz2

Im Frühjahr erzählten uns die #Onko­logie-Experten von @eisbachbio, dass sie auch an einem #Corona-Medikament arbeiten. Nun ist es „kurz vor der Klinik“. Allerdings: „Es hat gedauert, die Politik zu überzeugen“ … @SigridMaerz fragte nach: laborjournal.de/editorials/232…

Exploiting deep learning to develop sustainable COVID-19 inhibitors! Eisbach announce a collaboration with @uni_kl to develop small molecule inhibitors that will target the virus for the long-term. Read the press release here: eisbach.bio/press-release-… #mutations #DeepLearning

💊 Das #BMBF fördert gezielt die Entwicklung von aussichtsreichen Medikamenten gegen #COVID19. Jetzt starten 8 neue Forschungsvorhaben. BM Anja #Karliczek: "Wir brauchen weiterhin wirksame Medikamente gegen COVID-19." 👉 ow.ly/CGRr50FmyrF #Corona #Forschung

Congratulation to all COVID-19 projects funded by the BMBF! We are very proud to be part of this team effort against #SARS_CoV_2 and to continue our drug development with the @BMBF_Bund support